Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

Reprogramming inflammation via the DNA damage response-Metabolic axis control

Objetivo

Chronic inflammation underlies autoimmune diseases, cancer, and aging. Yet current therapies fail to address underlying metabolic dysregulation of one-carbon metabolism (1C) or unresolved DNA damage triggering oxidative DNA damage response (OxDDR) that fuel persistent immune activation cycles. Here, we want to decode and target the one-carbon metabolism–oxidative DNA damage response (1C–OxDDR) axis, a critical but underexplored driver of persistent immune activation. We hypothesize that chronic DNA damage and rewired 1C metabolism enforce stable, disease-promoting immune phenotypes. To test this, we will map 1C–OxDDR circuits in patient tissues and aging models using multi-omics, spatial transcriptomics, and metabolic flux profiling to define signatures of disease initiation, progression, and therapy resistance. We will identify novel disease drivers and develop precision small molecules, leveraging our track record in developing first-in-class inhibitors to MTHFD1&2, OGG1 and MTH1 using an AI-integrated drug design. Furthermore, we will pioneer catalytic medicine through OGG1 amplizymes, introducing a new therapeutic paradigm that introduces novel enzymatic functions to proteins rather than inhibiting them. These strategies will be validated in advanced preclinical systems, including organoids and humanized models to reprogram immune dysfunction without broad immunosuppression. This high-risk/high-gain program builds on our success in synthetic lethality and PARP inhibitors, aiming to deliver a new precision medicine platform for inflammation-driven diseases. By integrating mechanistic insight with innovative medicinal chemistry, RECODE seeks to break the vicious cycle of chronic inflammation, opening therapeutic opportunities across auto-immunity, cancer, and aging, with impact comparable to our previously discovered paradigm-shifting cancer therapies.

Ámbito científico (EuroSciVoc)

Este proyecto aún no se ha clasificado con EuroSciVoc.
Sugiera los ámbitos científicos que considere más relevantes y ayúdenos a mejorar nuestro servicio de clasificación.

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-ERC - HORIZON ERC Grants

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) ERC-2025-ADG

Ver todos los proyectos financiados en el marco de esta convocatoria

Institución de acogida

KAROLINSKA INSTITUTET
Aportación neta de la UEn
€ 2 500 000,00
Dirección
NOBELS VAG 5
171 77 STOCKHOLM
Suecia
Región
Östra Sverige Stockholm Stockholms län
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
Sin datos

Beneficiarios (1)